Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don G Morris

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cytotherapy|August 10, 2021
A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulinRutvij A Khanolkar, Amit Kalra, Megan Kinzel, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
JTO Clinical and Research Reports|April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint InhibitorsDaniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Annals of Surgical Oncology|June 21, 2005
Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcomaLloyd A Mack, Phil J Crowe, Jia Lin Yang, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Clinical Lung Cancer|February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint BlockadeVishal Navani, Daniel E Meyers, Yibing Ruan, et al.
Cancer Research|March 11, 2010
Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeuticChandini M Thirukkumaran, Michael J Nodwell, Kensuke Hirasawa, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cytotherapy|August 10, 2021
A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulinRutvij A Khanolkar, Amit Kalra, Megan Kinzel, et al.
Cancers|November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint InhibitorsDaniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
JTO Clinical and Research Reports|April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint InhibitorsDaniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Annals of Surgical Oncology|June 21, 2005
Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcomaLloyd A Mack, Phil J Crowe, Jia Lin Yang, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
Clinical Lung Cancer|February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint BlockadeVishal Navani, Daniel E Meyers, Yibing Ruan, et al.
Cancer Research|March 11, 2010
Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeuticChandini M Thirukkumaran, Michael J Nodwell, Kensuke Hirasawa, et al.
Pageof 3